Gilles Gallant
B.Pharm, Ph.D., FOPQ

Dr. Gallant is a consultant/advisor to biotechnology and pharmaceutical companies developing oncology drugs. He recently served as Chief Development Officer at Mythic Therapeutics, responsible for the strategy, direction and execution of the company’s clinical development program. He also serves as a scientific advisor for Iteru Systems and is the Founder and Principal Consultant of GG Biotech Consulting LLC. Previously, Dr. Gallant was Senior Vice President and Global Head of Oncology Clinical Development at Daiichi Sankyo, where he led the clinical development and global approval of the antibody-drug conjugate (ADC) Enhertu® (fam-trastuzumab deruxtecan-nxki) for the treatment of advanced breast cancer, gastric cancer and non-small cell lung cancer. Dr. Gallant also held leadership roles of increasing responsibility at Bristol-Myers-Squibb, Human Genome Sciences and BioMarin. Dr. Gallant earned a Ph.D. in medicinal chemistry and a B.Pharm from the Université de Montréal and is a Fellow of the Order of Pharmacists of Québec.